Neurocritical Care News

Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular glue degraders to address protein accumulation related to Alzheimer’s disease and other neurologic conditions.

Top-line results of a phase 2 clinical trial for an adiposederived autologous mesenchymal stem cell therapy to address mild to moderate relapsing-remitting MS found the treatment improved mental and physical health at 52 weeks.

Consuming a diet with more plant-based foods and the right kind of fats while engaging in daily exercise are sure-fire paths to maintaining brain health, according to speakers at the Lifestyle Medicine Conference.

ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for companies that advance novel therapeutics for a range of neurological conditions.

A progressive neurodegenerative condition, ALS has no cure, with diagnosis often a result of protracted clinical evaluation that may take more than a year to accurately determine.

An independent data monitoring committee has ruled that a phase 3 clinical trial investigating vidofludimus calcium for relapsing MS may continue as originally planned, according to the therapeutic’s manufacturer.

Results from a clinical trial examining intracranial stimulation using a novel device in those with mild Alzheimer’s disease showed that treatment led to improvements in memory, cognitive function and blood flow.

Health Canada has approved Daybue to treat Rett syndrome in patients aged 2 years and older, according to manufacturer Acadia Pharmaceuticals.

Early initiation and continuation of Kesimpta in those with relapsing MS was associated with lower rates of disability worsening up to 6 years compared with those who switched medication, according to a presentation at ECTRIMS 2024.

Topline results from the phase 3 SAPPHIRE clinical trial showed that an investigational muscle-targeted therapy improved motor function in patients with spinal muscular atrophy compared with placebo as early as week 8.